In contrast, a meta-analysis of nine studies with 5143 patients, performed by Phrommintikul et al. [7], indicated an increased risk of all-cause mortality among patients with high hemoglobin levels treated with EPO; the same study showed similar incidences of acute myocardial infarction in the patients. This evidence concerns the gene EPO and acute myocardial infarction.